Optimal modeling of anti-breast cancer candidate drugs screening based on multi-model ensemble learning with imbalanced data.

The imbalanced data makes the machine learning model seriously biased, which leads to false positive in screening of therapeutic drugs for breast cancer. In order to deal with this problem, a multi-model ensemble framework based on tree-model, linear model and deep-learning model is proposed. Based on the methodology constructed in this study, we screened the 20 most critical molecular descriptors from 729 molecular descriptors of 1974 anti-breast cancer drug candidates and, in order to measure the pharmacokinetic properties and safety of the drug candidates, the screened molecular descriptors were used in this study for subsequent bioactivity, absorption, distribution metabolism, excretion, toxicity, and other prediction tasks.